Zai Lab Limited (ZLAB)

Market Cap	2.31B -31.3%
Revenue (ttm)	453.28M +8.4%
Net Income	-178.12M
EPS	-1.70
Shares Out	112.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	903,108
Open	20.46
Previous Close	20.33
Day's Range	20.39 - 21.33
52-Week Range	15.96 - 44.34
Beta	0.84
Analysts	Strong Buy
Price Target	44.60 (+116.61%)
Earnings Date	May 7, 2026

About ZLAB

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 1,784
• Stock Exchange: NASDAQ
• Ticker Symbol: ZLAB
• Website: https://www.zailaboratory.com

Financial Performance

In 2025, Zai Lab's revenue was $460.16 million, an increase of 15.33% compared to the previous year's $398.99 million. Losses were -$175.54 million, -31.73% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for ZLAB stock is "Strong Buy." The 12-month stock price target is $44.6, which is an increase of 116.61% from the latest price.

Price Target

$44.6

(116.61% upside)

Analyst Consensus: Strong Buy